日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.

利拉夫替尼选择性抑制FGFR2的临床耐药机制。

Ellis H, Balasooriya E R, Varkaris A, Hajian B, Wan J, Shekhar M, Gritti I, Vijay V, Albertelli L, Piot S, Lau K, Kehlmann A, Chevalier N, Nugent F W, Zhen Y, Silveira V S, Sellers W R, Corcoran R B, Juric D, Bardeesy N

Identification of a Force-Induced Sox9(+)Acan(+) Transitional Subpopulation Linked to FGF2-FGFR2-ERK Signaling in Orthodontic Bone Remodeling.

鉴定与正畸骨重塑中 FGF2-FGFR2-ERK 信号传导相关的力诱导 Sox9(+)Acan(+) 过渡亚群。

Tan Miao, He Minyu, Zong Mingrui, Tang Qiya, Liu Yinan, Deng Jiaju, Huang Shun, Lei Xiaoxiao, Li Jie, Huang Lan

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

PI3Kα抑制剂和降解剂Inavolisib可利用FGFR2增强PIK3CA突变实体瘤患者和临床前模型的疗效。

Juric Dejan, Song Kyung, Johnson Radia M, Accordino Melissa K, Bedard Philippe L, Cervantes Andrés, Gambardella Valentina, Hamilton Erika, Italiano Antoine, Kalinsky Kevin, Krop Ian E, Oliveira Mafalda, Saura Cristina, Schmid Peter, Turner Nicholas C, Varga Andreea, Gendreau Steven, Hwang Michael S, Kuang Zheng, Lau Jeffrey T, Lin Eva, Pham Trang, Maddalo Danilo, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Martin Scott, Sodir Nicole M, Sokol Ethan S, Whitfield Zachary J, Wong Alice, Yauch Robert L, Aimi Junko, Cheeti Sravanthi, Fredrickson Jill, Hilz Stephanie, Hafner Marc, Hutchinson Katherine E, Jin Yanling, Peters Ubong, Zingg Daniel, Royer-Joo Stephanie, Shankar Noopur, Schutzman Jennifer L, Jhaveri Komal L, Dey Anwesha

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

对利拉夫格拉替尼的复发性耐药突变可指导 FGFR2 驱动肿瘤的治疗顺序。

Facchinetti Francesco, Hollebecque Antoine, Barbé Rémy, Jang Dong Man, Alonso-De-Castro Beatriz, Brayé Floriane, Bigot Ludovic, Nobre Catline, Da Silva Alice, Méteau Mélissandre, Delavigne Mathis, Soares Miguel, Italiano Antoine, Rodriguez Julieta, Mosele Fernanda, Beshiri Kristi, Ducreux Michel, Boilève Alice, Nikolaev Sergey, Alonso-Garcia Inmaculada, Vasseur Damien, Smolenschi Cristina, Bourien Héloise, Cotteret Sophie, Samaniego Juliette, Bernard Elsa, Nicotra Claudio, Ngo-Camus Maud, Nakazawa Seshiru, Tselikas Lambros, Badoual Cécile, André Fabrice, Eck Michael J, Olaussen Ken A, Loriot Yohann, Friboulet Luc

Role of lipid rafts in the FGFR2c-mediated oncogenic signaling by involvement of TRPA1 channel in pancreatic ductal adenocarcinoma cells.

脂筏通过 TRPA1 通道参与胰腺导管腺癌细胞中 FGFR2c 介导的致癌信号传导发挥作用。

Mancini Vanessa, Manganelli Valeria, Garofalo Tina, Sorice Maurizio, Raffa Salvatore, Scullari Dafne, Ranieri Danilo, Belleudi Francesca

Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301

一项针对伴有FGFR2基因融合或重排的晚期胆管癌成人患者的III期临床试验:英菲格替尼对比吉西他滨/顺铂方案的疗效:PROOF 301试验的结果及提前终止的反思

Abou-Alfa, G K; Borbath, I; Roychowdhury, S; Goyal, L; Lamarca, A; Macarulla, T; Shroff, R T; Oh, D-Y; Tamaş, C; Savastano, D M; van Veenhuyzen, D F; Xu, C; Freas, E; Solanas, J; Javle, M M

Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer

对FGFR2b及其与晚期胃癌关键生物标志物、肿瘤内异质性和生存率的相关性进行全面分析

Kwak, Yoonjin; Kim, Tae-Yong; Lee, Hye Seung; Nam, Soo Kyung; Oh, Hyeon Jeong; Oh, Do-Youn; Im, Seock-Ah

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer.

阻断 SHP2 可增强 FGFR2 抑制剂的疗效,并克服 FGFR2 扩增型胃癌的耐药性。

Zhang Yue, Wang Hanbing, Wei Yutao, Pan Yunfeng, Song Xueru, Shao Jie, Yu Lixia, Shi Tao, Wang Yue

Identification of novel FGFR2::TXLNB Fusion in a polymorphous low-grade neuroepithelial tumor of the young

在年轻人多形性低级别神经上皮肿瘤中鉴定出新的FGFR2::TXLNB融合基因

Hu, Sha-Sha; Tan, Tian-Yuan; Yan, Wei; Wang, Bo

2H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as novel selective fibroblast growth factor receptor 2 (FGFR2) inhibitors

2H-吡唑并[3,4-d]嘧啶-4-胺衍生物作为新型选择性成纤维细胞生长因子受体2 (FGFR2) 抑制剂

Wu, Pinglian; Tian, Zhaodi; Shen, Weizhong; Xun, Qiuju; Tian, Yuan; Li, Huiqiong; Yang, Bowen; Chang, Shaohua; Huang, Weixue; Wang, Zhen; Ding, Ke; Ma, Dawei